Biotech · Private company
Healx AI
Track this companyFree. Adds Healx AI to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- OV101Phase 3 · Angelman SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- OV101 Regimen 1Phase 2 · Angelman SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- OV101 regimen 2Phase 2 · Angelman SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman SyndromePHASE3 · TERMINATED · started Jan 31, 2019ClinicalTrials.gov NCT03882918 · fetched Nov 12, 2026
- A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)PHASE2 · COMPLETED · started Sep 10, 2018ClinicalTrials.gov NCT03694275 · fetched Nov 12, 2026
- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic EncephalopathiesPHASE2 · COMPLETED · started Aug 8, 2018ClinicalTrials.gov NCT03650452 · fetched Nov 12, 2026
- Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic EncephalopathiesPHASE1_PHASE2 · COMPLETED · started Aug 17, 2017ClinicalTrials.gov NCT03166215 · fetched Nov 12, 2026
- A Study in Adults and Adolescents With Angelman Syndrome (STARS)PHASE2 · COMPLETED · started Jan 1, 2016ClinicalTrials.gov NCT02996305 · fetched Nov 12, 2026